Xcelerate Business Summary

Xcelerate, Inc. (XCRT) operates as a medical technology incubator and healthcare services provider, generating revenue through intellectual property (IP) licensing, AI-driven virtual health fees, and clinical care operations. Following the strategic divestiture of its ESN Group consumer health assets in late 2025, the company has consolidated its operations into two primary segments: Medical Technology Acquisition, which identifies and adapts non-medical engineering patents for clinical applications, and Virtual Health Technology, led by its AfiyaSasa Africa subsidiary. The 2026 business plan focuses on the commercial rollout of an AI-assisted patient portal in Tanzania and the acquisition of clinical care settings to trial proprietary surgical guidance tools. Xcelerate competes in a specialized niche alongside larger clinical research organizations and micro-cap med-tech firms such as Novartis, Catalent, BioCorRx Inc., and Ethema Health Corp., positioning itself as a high-agility bridge between raw engineering innovation and underserved clinical markets. The leadership team is led by Chairman and CEO Michael F. O’Shea, a forensic accountant and former investigator for federal agencies including the FBI and FDIC, who spearheaded the company’s strategic pivot in 2020. Technical development is overseen by Chief Science Officer Dr. Anja Glisovic-Rosch, a former R&D leader at the Fraunhofer Institute with an extensive portfolio of medical device patents. The company’s strategic direction is further bolstered by a high-pedigree Advisory Board that includes Nobel Laureate Dr. Barry Marshall and renowned neurosurgeon Dr. Dilan B. Ellegala. Notable board members include Independent Director Jason Householder, a healthcare banking veteran, while recent private placements and the ESN sale proceeds provide the capital structure for the firm’s 2026 expansion into AI-assisted diagnostics and international clinical care settings.